GlassScriptPhysician profile
Jessica E Rayner
NPI 1679000525
$5,211.29
in general payments reported to CMS, 2019-2025
28 companies · $901 in 2025
The $901 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,557 · 2022: $892 · 2023: $845 · 2024: $1,017 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712 · Long Term Medical Supply Or Device Loan: $50.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,712.21 |
| Long Term Medical Supply Or Device Loan | $50.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,294.91 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $697.93 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $614.13 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $445.16 | 2022-2025 | Repatha, Repatha |
| Endologix LLC | $284.96 | 2024 | |
| Janssen Pharmaceuticals, INC | $266.84 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $244.42 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $165.08 | 2021-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $163.94 | 2021 | |
| Chiesi USA, INC. | $134.00 | 2021 | |
| Scpharmaceuticals INC. | $114.97 | 2024-2025 | |
| Vifor Pharma, INC. | $90.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.75 | 2021-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $79.07 | 2021-2022 | |
| Baxter Healthcare | $79.07 | 2022-2025 | Hillrom - Eli 280 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $71.84 | 2025 | Watchman Flx |
| Edwards Lifesciences Corporation | $54.74 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Alnylam Pharmaceuticals INC. | $54.07 | 2021 | |
| Amarin Pharma, INC. | $48.10 | 2021-2022 | |
| Pfizer INC. | $47.98 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $30.21 | 2023 | Inpefa |
| Novo Nordisk INC | $26.04 | 2025 | Wegovy |
| Abbott Laboratories | $24.22 | 2024 | Cardiomems |
| Cardiovascular Systems INC. | $23.63 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $22.63 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.20 | 2025 | Evkeeza |
| Medicomp INC | $19.19 | 2023 | Telepatch Cardiac Monitor |
| Medtronic, INC. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Rayner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.